aluates Reports

$ 0.0

Automative

Global Age-Related Macular Degeneration (AMD) Therapeutics Market Research Report 2024

Published Date: January 2024

Report Code: QYRE-Auto-19U14299

Global Age Related Macular Degeneration AMD Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Age-Related Macular Degeneration (AMD) Therapeutics Market Research Report 2024

Code: QYRE-Auto-19U14299

Report

January 2024

Pages:72

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Amgen Inc

Bausch Health Companies Inc.

F Hoffmann La Roche Ltd

Novartis

Regeneron Pharmaceuticals Inc

Age-Related Macular Degeneration (AMD) Therapeutics Market Size

The global Age-Related Macular Degeneration (AMD) Therapeutics market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 11400 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.

Age-Related Macular Degeneration (AMD) Therapeutics Market

Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Age-Related Macular Degeneration (AMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-Related Macular Degeneration (AMD) Therapeutics.

Report Scope

The Age-Related Macular Degeneration (AMD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age-Related Macular Degeneration (AMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Age-Related Macular Degeneration (AMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Age-Related Macular Degeneration (AMD) Therapeutics Market Report

Report Metric	Details
Report Name	Age-Related Macular Degeneration (AMD) Therapeutics Market
Accounted market size in 2023	US$ 7725.7 million
Forecasted market size in 2030	US$ 11400 million
CAGR	5.8%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Wet AMD Dry AMD
Segment by Application	Hospital Clinic Research Institute Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen Inc., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Age-Related Macular Degeneration (AMD) Therapeutics Market growing?

Ans: The Age-Related Macular Degeneration (AMD) Therapeutics Market witnessing a CAGR of 5.8% during the forecast period 2024-2030.

What is the Age-Related Macular Degeneration (AMD) Therapeutics Market size in 2030?

Ans: The Age-Related Macular Degeneration (AMD) Therapeutics Market size in 2030 will be US$ 11400 million.

Who are the main players in the Age-Related Macular Degeneration (AMD) Therapeutics Market report?

Ans: The main players in the Age-Related Macular Degeneration (AMD) Therapeutics Market are Amgen Inc., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc.

What are the Application segmentation covered in the Age-Related Macular Degeneration (AMD) Therapeutics Market report?

Ans: The Applications covered in the Age-Related Macular Degeneration (AMD) Therapeutics Market report are Hospital, Clinic, Research Institute, Other

What are the Type segmentation covered in the Age-Related Macular Degeneration (AMD) Therapeutics Market report?

Ans: The Types covered in the Age-Related Macular Degeneration (AMD) Therapeutics Market report are Wet AMD, Dry AMD

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Wet AMD

1.2.3 Dry AMD

1.3 Market by Application

1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Research Institute

1.3.5 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Perspective (2019-2030)

2.2 Age-Related Macular Degeneration (AMD) Therapeutics Growth Trends by Region

2.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Dynamics

2.3.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends

2.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers

2.3.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges

2.3.4 Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Revenue

3.1.1 Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Age-Related Macular Degeneration (AMD) Therapeutics Revenue

3.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio

3.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2023

3.5 Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Area Served

3.6 Key Players Age-Related Macular Degeneration (AMD) Therapeutics Product Solution and Service

3.7 Date of Enter into Age-Related Macular Degeneration (AMD) Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Type

4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2025-2030)

5 Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Application

5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2019-2030)

6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024)

6.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2019-2030)

7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024)

7.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2019-2030)

9.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen Inc.

11.1.1 Amgen Inc. Company Detail

11.1.2 Amgen Inc. Business Overview

11.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction

11.1.4 Amgen Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

11.1.5 Amgen Inc. Recent Development

11.2 Bausch Health Companies, Inc.

11.2.1 Bausch Health Companies, Inc. Company Detail

11.2.2 Bausch Health Companies, Inc. Business Overview

11.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction

11.2.4 Bausch Health Companies, Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

11.2.5 Bausch Health Companies, Inc. Recent Development

11.3 F. Hoffmann-La Roche Ltd.

11.3.1 F. Hoffmann-La Roche Ltd. Company Detail

11.3.2 F. Hoffmann-La Roche Ltd. Business Overview

11.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Introduction

11.3.4 F. Hoffmann-La Roche Ltd. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

11.3.5 F. Hoffmann-La Roche Ltd. Recent Development

11.4 Novartis AG

11.4.1 Novartis AG Company Detail

11.4.2 Novartis AG Business Overview

11.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Introduction

11.4.4 Novartis AG Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

11.4.5 Novartis AG Recent Development

11.5 Regeneron Pharmaceuticals Inc.

11.5.1 Regeneron Pharmaceuticals Inc. Company Detail

11.5.2 Regeneron Pharmaceuticals Inc. Business Overview

11.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction

11.5.4 Regeneron Pharmaceuticals Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

11.5.5 Regeneron Pharmaceuticals Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Amgen Inc

Bausch Health Companies Inc.

F Hoffmann La Roche Ltd

Novartis

Regeneron Pharmaceuticals Inc

List of Tables

Table 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Wet AMD

Table 3. Key Players of Dry AMD

Table 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Region (2019-2024)

Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Region (2025-2030)

Table 10. Age-Related Macular Degeneration (AMD) Therapeutics Market Trends

Table 11. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers

Table 12. Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges

Table 13. Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints

Table 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players (2019-2024)

Table 16. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2023)

Table 17. Ranking of Global Top Age-Related Macular Degeneration (AMD) Therapeutics Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Age-Related Macular Degeneration (AMD) Therapeutics Product Solution and Service

Table 21. Date of Enter into Age-Related Macular Degeneration (AMD) Therapeutics Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2019-2024)

Table 25. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2025-2030)

Table 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2019-2024)

Table 29. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2025-2030)

Table 31. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 46. Amgen Inc. Company Detail

Table 47. Amgen Inc. Business Overview

Table 48. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product

Table 49. Amgen Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024) & (US$ Million)

Table 50. Amgen Inc. Recent Development

Table 51. Bausch Health Companies, Inc. Company Detail

Table 52. Bausch Health Companies, Inc. Business Overview

Table 53. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product

Table 54. Bausch Health Companies, Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024) & (US$ Million)

Table 55. Bausch Health Companies, Inc. Recent Development

Table 56. F. Hoffmann-La Roche Ltd. Company Detail

Table 57. F. Hoffmann-La Roche Ltd. Business Overview

Table 58. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product

Table 59. F. Hoffmann-La Roche Ltd. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024) & (US$ Million)

Table 60. F. Hoffmann-La Roche Ltd. Recent Development

Table 61. Novartis AG Company Detail

Table 62. Novartis AG Business Overview

Table 63. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product

Table 64. Novartis AG Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024) & (US$ Million)

Table 65. Novartis AG Recent Development

Table 66. Regeneron Pharmaceuticals Inc. Company Detail

Table 67. Regeneron Pharmaceuticals Inc. Business Overview

Table 68. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product

Table 69. Regeneron Pharmaceuticals Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024) & (US$ Million)

Table 70. Regeneron Pharmaceuticals Inc. Recent Development

Table 71. Research Programs/Design for This Report

Table 72. Key Data Information from Secondary Sources

Table 73. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Wet AMD Features

Figure 4. Dry AMD Features

Figure 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2023 VS 2030

Figure 7. Hospital Case Studies

Figure 8. Clinic Case Studies

Figure 9. Research Institute Case Studies

Figure 10. Other Case Studies

Figure 11. Age-Related Macular Degeneration (AMD) Therapeutics Report Years Considered

Figure 12. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Region: 2023 VS 2030

Figure 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players in 2023

Figure 16. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2023

Figure 18. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2019-2030)

Figure 20. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2019-2030)

Figure 24. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Region (2019-2030)

Figure 32. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2019-2030)

Figure 40. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2019-2030)

Figure 44. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Amgen Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

Figure 47. Bausch Health Companies, Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

Figure 48. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

Figure 49. Novartis AG Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

Figure 50. Regeneron Pharmaceuticals Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2019-2024)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

Figure 53. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions